Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Drops By 21.4%

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the target of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totalling 535,000 shares, a decrease of 21.4% from the December 31st total of 680,800 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average daily volume of 636,800 shares, the days-to-cover ratio is presently 0.8 days.

Tiziana Life Sciences Stock Down 0.3 %

TLSA opened at $0.69 on Friday. The company has a 50 day moving average of $0.82 and a 200 day moving average of $0.94. Tiziana Life Sciences has a 12 month low of $0.41 and a 12 month high of $1.74.

Hedge Funds Weigh In On Tiziana Life Sciences

A hedge fund recently raised its stake in Tiziana Life Sciences stock. Zhang Financial LLC increased its position in Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 34.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 93,187 shares of the company’s stock after acquiring an additional 23,800 shares during the quarter. Zhang Financial LLC owned about 0.09% of Tiziana Life Sciences worth $65,000 at the end of the most recent quarter.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.